Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Gut|July 15, 2014
Exercise and associated dietary extremes impact on gut microbial diversitySiobhan F Clarke, Eileen F Murphy, Orla O'Sullivan, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
British Journal of Haematology|July 18, 2020
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapyThomas A Fox, Ethan Troy-Barnes, Amy A Kirkwood, et al.
Hemasphere|June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysisMaeve A O'Reilly, William Wilson, David Burns, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Cancer Research Communications|June 4, 2026
CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX StudyClaire Roddie, William Day, Meera Raymond, et al.
Molecular Therapy. Advances|May 15, 2026
A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCLClaire Roddie, Juliana Dias, Gordon Weng-Kit Cheung, et al.
British Journal of Haematology|March 8, 2026
Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survivalMaeve A O'Reilly, William Wilson, Bernard Maybury, et al.
Blood|February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphomaClaire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Pageof 9